Imiglitazar is primarily researched for its potential in managing type 2 diabetes. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), targeting both PPAR-alpha and PPAR-gamma receptors. This dual action helps in improving insulin sensitivity and regulating blood glucose levels. By activating PPAR-gamma, it enhances the body's response to insulin, while PPAR-alpha activation aids in lipid metabolism, reducing triglyceride levels and improving overall lipid profiles. Its application is focused on providing a comprehensive approach to diabetes management, addressing both glycemic control and lipid abnormalities. However, its clinical use is still under investigation due to concerns about safety and side effects.